Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio Q2 Revenues Increase 10 Percent

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that its revenues for the second quarter improved 10 percent year over year, paced by a 60 percent growth in grant revenues.

For the three months ended June 30, the South Easton, Mass.-based firm recorded total revenues of $357,736, up from $324,908 a year ago. While revenues from PCT products and services retreated 8 percent to $196,522 from $224,384, grant revenues increased to $161,214 from $100,524.

Pressure Bio recorded a net loss in the second quarter of $1.1 million, or $.10 per share, compared to a net loss of $509,692, or $.11 per share, a year ago.

The company used 11.5 million shares to calculate its net loss per share figure for the recently completed quarter, compared to 10.2 million shares in Q2 2012.

R&D spending came in at $260,408, up 2 percent from $256,307 a year ago. SG&A costs was up 36 percent to $871,525 from $642,188.

The firm finished the quarter with $113,663 in cash and cash equivalents.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.